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Cardiovascular disease remains the leading cause of mortality in the US and worldwide, and no widespread screening for this
number one killer has been implemented. Traditional risk factor assessment does not fully account for the coronary risk and
underestimates the prediction of risk even in patients with established risk factors for atherosclerosis. Coronary artery calcium
(CAC) represents calci�ed atherosclerosis in the coronary arteries. It has been shown to be the strongest predictor of adverse
future cardiovascular events and provides incremental information to the traditional risk factors. CAC consistently outperforms
traditional risk factors, including models such as Framingham risk to predict future CV events. It has been incorporated into both
the European and American guidelines for risk assessment. CAC is the most robust test today to reclassify individuals based on
traditional risk factor assessment and provides the opportunity to better strategize the treatments for these subjects (converting
patients from intermediate to high or low risk). CAC progression has also been identi�ed as a risk for future cardiovascular events,
with markedly increased events occurring in those patients exhibiting increases in calci�cations over time. e exact intervals for
rescanning is still being evaluated.
1. Introduction
Imaging of atherosclerosis in the coronary arteries represents
advanced atheroma and has been shown to be the strongest
predictor of future cardiovascular (CV) events, outperform-
ing traditional risk factors, in�ammatory and other biomark-
ers, and other tests of atherosclerosis such as carotid intimal
media thickness (CIMT), endothelial function, and ankle-
brachial index. e traditional cardiovascular risk assess-
ments underestimate the prediction of CV risk, and many
individuals still suffer events in the absence of established
risk factors for atherosclerosis [1]. Coronary artery calcium
(CAC) has been shown to be the strongest independent
predictor of future adverse cardiovascular events and also
provides incremental information to the traditional cardio-
vascular risk factors assessment. It can be used to risk stratify
asymptomatic individuals, improve the risk prediction pro-
vided by Framingham risk score (FRS), and follow the burden
of calci�ed pla�ue over time, which is associated with further
risk strati�cation beyond baseline score.
�. C�C as a Ris� Strati�cation Too�
ere is tremendous evidence available that supports the role
of CAC as the best risk strati�er for asymptomatic individuals
[2]. CAC has been persistently shown to have superior
independent and incremental predictor of CVD compared
with traditional risk factors [3–13]. In the St. Francis Heart
Study [3], a prospective population-based study of over 4000
persons followed for 4.3 years, a calcium score>100 predicted
all atherosclerotic cardiovascular disease events, all coronary
events, and the sumof nonfatalMI and coronary death events
with relative risks of 9.5 to 10.7 at 4.3 years, as compared
to patients with scores <100. is prospective study strongly
demonstrated the ability to utilize this test to rule out patients
who do not need therapy. CAC was predictive of coronary
events, while highly sensitive CRP was not.
e Multi-Ethnic Study of Atherosclerosis (MESA), spo-
nsored by the National Heart, Lung and Blood Institute, was
a prospective population-based study of four different ethnic
groups (whites, Hispanics, Asians, and African Americans)
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which provided a detailed insight into the role of CAC in risk
assessment. Detrano et al. [4] showed that risk for coronary
events increased by a factor of 7.73 among subjects with
CAC scores between 101 and 300 and by a factor of 9.67 with
CAC score above 300 when compared with CAC score 0 in
6,772 MESA participants. is 8-fold increase event rate was
aer multivariate adjustment for many factors, including
C-reactive protein (which added no predictive value) and
traditional risk factors. Across four ethnic groups, a doubling
of CAC increased the risk of major coronary event by 15
to 35% and the risk of any coronary event by 18% to 39%.
CAC provided an incremental value for prediction of major
coronary events when added to the standard risk factors
(0.83 versus 0.79 area under the curve for risk factors alone
versus risk factors plus CAC, 𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃𝑃). Budoff et al. [5]
showed CAC to be an independent predictor of mortality
aer controlling for age, gender, ethnicity, and cardiac risk
factors (model chi-square = 2.017, 𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃𝑃𝑃), in a registry
of 25,253 asymptomatic individuals. CAC was shown to have
signi�cant incremental value compared with risk factors
resulting in a higher concordance index (0.81 versus 0.61;
𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃𝑃𝑃). Risk-adjusted relative risk ratios for CAC scores
11 to 100, 101 to 299, 300 to 399, 400 to 699, 700 to 999, and
>1000 were 2.2-, 4.5-, 6.4-, 9.2-, 10.4-, and 12.5-fold when
compared with CAC score 0, respectively (𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃𝑃𝑃).
e South BayHeartWatch [6] was the �rst study to com-
pare the prognostic ability of CAC and highly-sensitive C-
reactive protein (CRP).is study was a prospective observa-
tional population-based study on 1,461 asymptomatic adults
with coronary risk factors who underwent CAC score and
were followed prospectively for up to 8.5 years for nonfatal
myocardial infarctions or coronary heart disease (CHD)
deaths. is study demonstrated that CAC scores were
incremental in predicting cardiac risk, and the relative risk
(RR) of hard cardiac events (MI and death) increased from
1 to 4.9 with increasing calcium tertiles (𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃𝑃), while
highly sensitive CRP failed to add independent prognostic
value for hard cardiac events. Compared with CAC score of
zero, a CAC score of more than 300 was signi�cant predictor
(hazard ratio HR, 3.9; 95% con�dence interval CI, 2.1–7.3;
𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃𝑃) of nonfatal myocardial infarctions or CHD
deaths. Across FRS categories (0–9%, 10%–15%, 16%–20%,
and ≥21%), CACS was predictive of risk among patients
with an FRS higher than 10% (𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃𝑃𝑃 but not with an
FRS less than 10%. FRS plus CAC resulted in a signi�cantly
greater mean area under the curve for the receiver operating
characteristics curve compared with FRS alone (0.68 versus
0.63; 𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃𝑃).
Kondos et al. reported a 37-month followup on 5,635 ini-
tially asymptomatic low- to intermediate-risk adults (mean
age 𝑃𝑃 ± 9 years) [7]. Patients with scores >170 had a relative
risk for developing hard cardiac events of 7.24 (95% CI,
2.01–26.15), aer multivariable analysis was performed with
adjustment for age and other CAD risk factors. e presence
of CAC provided incremental prognostic information over
age and other risk factors.
A cohort of 10,377 asymptomatic individuals undergoing
cardiac risk factor evaluation and CAC measure with EBT
reported a mean followup of 5.0 years [8]. In a risk-adjusted
model, CAC was an independent predictor of mortality
(𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃𝑃). is large observational data series shows
that coronary calcium provides independent incremental
information in addition to traditional risk factors in the
prediction of all-cause mortality.
Taylor et al. studied a nonreferred cohort of healthy men
and women aged 40 to 50 who were evaluated with measured
coronary risk variables and coronary calcium detected with
electron beam tomography [9]. Incident acute coronary
syndromes and sudden cardiac death were ascertained via
annual telephonic contacts, with a mean follow-up of 3 years.
Coronary calcium was found in 22.4% of men and 7.9% of
women. A total of 9 acute events occurred inmen, including 7
of 364menwith coronary calcium (1.95%) and 2 of 1,263men
without coronary calcium (0.16%; 𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃𝑃𝑃 by logrank).
No events occurred in women. In these men, coronary cal-
cium was associated with an 11.8-fold increased risk for inci-
dent CAD (𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃𝑃) aer controlling for the Framingham
risk score.e study concluded that “In young, asymptomatic
men, the presence of coronary artery calci�cation provides
substantial, cost-effective, independent prognostic value in
predicting incident CHD that is incremental to measured
coronary risk factors.” Similar to multiple prior studies,
addition of C-reactive protein added no clinical value.
More recently, the Heinz Nixdorf Recall (HNR) study
performed a prospective, population-based study, and aer
5.1 years, primary events occurred in 93 (2.3%) of 4137
participants (30% females) [13]. e event rate increased
with the degree of CAC. Most importantly, the event rate in
women with CAC ≥400 was similar to that in men (8.3% in
5 years). is means that the main determinant for CV risk
is the degree of plaque burden. In the HNR study, the FRS
reached an AUC of 0.681, and CAC improved the c-statistics
signi�cantly to 0.749 (𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃𝑃𝑃𝑃 [13].
A paper by Yeboah et al recently demonstrated that the
best predictor of future CV events among any test or algo-
rithm studied was CAC testing [14]. Aer 7.6-year median
follow-up in MESA, CAC, ankle-brachial index, and family
history were independently associated with incident CHD in
multivariable analyses (HR, 2.60 [95% CI, 1.94–3.50]; HR,
0.79 [95% CI, 0.66–0.95]; HR, 2.18 [95% CI, 1.38–3.42],
resp.). Carotid intima-media thickness and brachial �ow-
mediated dilation were not associated with incident CHD in
multivariable analyses (HR, 1.17 [95%CI, 0.95–1.45] andHR,
0.95 [95% CI, 0.78–1.14]). Coronary artery calcium afforded
the highest increment in improvement in AUC (0.623 versus
0.784, 𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃𝑃𝑃). ey concluded that CAC provided
superior discrimination and risk reclassi�cation compared
with other risk markers.
CAC has been shown to have superior predictive and
incremental value in risk strati�cation of asymptomatic
individuals. It has been suggested for use in risk strati�cation
of intermediate risk, low to intermediate risk, and diabetic
individuals in recent AHA/ACC guidelines [2, 15]. e
role of baseline CAC score may provide a useful option to
strategize preventive therapeutic and aggressive treatment
strategies due to its ability to reclassify low-risk populations
as determined by the traditional risk assessment tools.
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�. �et �eclassi�cation �it� Coronary
Artery Calci�cation
Pencina et al. [16] introduced the concept of net reclas-
si�cation improvement (NRI) which measures the extent
to which people with and without events are appropriately
reclassi�ed into clinically accepted higher- or lower-risk
categories with the addition of a new marker. CAC has
been shown to reclassify the risk assessment based on FRS
and National Cholesterol Education Adult Treatment Panel
(ATP) III guidelines into either higher- or lower-risk cate-
gories based on CAC score information [13, 17, 18]. e net
reclassi�cation improvement in MESA for the entire cohort
was 25% [15]. ose who were upgraded had in 16.4% an
event, and those who were downgraded had an event in 2.3%.
In the intermediate risk score cohort, 16% were reclassi�ed
at high risk and 39% at low risk which resulted in a net
reclassi�cation improvement of 55% [17].
A more recent analysis from MESA with longer follow-
up [14] demonstrated net reclassi�cation of almost 66%.
For incident CHD, the net reclassi�cation improvement
with CAC was 0.659, orders of magnitude were better than
brachial �ow-mediated dilation 0.024, ankle-brachial index
was 0.036, carotid intima-media thickness was 0.102, family
history was 0.160, and high-sensitivity CRP was 0.079. In
the HNR study, 57% of male and 64% of female subjects
in the intermediate group were reclassi�ed as the low-
risk category [13]. Only 6.6% of the total intermediate
group remained in the intermediate category and would
need reassessment during follow-up or additional analysis
of signs of atherosclerosis in other vascular territories. e
HNR study yielded a net reclassi�cation improvement for
hard coronary events of 30.6% for the 6%–20%/10-year risk
threshold. ere was signi�cant improvement in the area
under the curve from 0.681 to 0.749 (𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃𝑃𝑃 and from
0.653 to 0.755 (𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃𝑃𝑃𝑃 by adding CAC scores to
the FRS and National Cholesterol Education Panel ATP III
categories, respectively. Also the Rotterdam study presented
the effect of reclassi�cation in the intermediate risk group
de�ned as 10%–20% 10-year risk [18]. A total of 52% of
men and women were reclassi�ed, all into more accurate
categories. In asymptomatic patients, the S. Francis Heart
Study demonstrated reclassi�cation in 73% of intermediate-
risk patients [3].
In theMESA study, 23% of those who experienced events
were reclassi�ed to high risk, and 13% without events were
reclassi�ed to low risk using CAC in addition to traditional
risk factors [17]. Also, 90% of women in MESA study were
found to be at low risk. In this group, >30% of women were
found to have CAC score >0, whereas the prevalence of
signi�cant CAC (≥300) was four percent [12]. ese subjects
would have not received preventive therapeutic treatments
based on traditional risk factor assessment alone. However,
the use of CAC in these populations may be helpful to
identify individuals who are in need of these therapeutic
treatments. Serial measurement of CAC over time also
provides useful information about the coronary risk of these
individuals. Multiple guidelines support the utility of CAC
in asymptomatic persons to risk stratify individuals. Use of
CAC in symptomatic populations has been demonstrated to
provide a cost-effective �lter prior to invasive angiography
[15, 19].
4. Absence of Coronary Artery Calcium
e risk for future adverse cardiovascular events increases
with increasing CAC scores; however, the absence of CAC
presents a very unique situation which is associated with
very low-risk status for the individual (10-year event rate of
∼1%) [2, 11, 15, 20]. It has been proposed that those without
calci�cation may be at such a low-risk status, that further
intervention with pharmacology may be unnecessary. e
absence of CAC is associated with a very low risk of future
cardiovascular events, presence of severe CAD, myocardial
perfusion abnormalities and likelihood of ACS. e absence
of CAC on noncontrast CT identi�es an extremely low-risk
population and potentially can serve as excellent indicator of
low likelihood of present and future risk of CAD. For symp-
tomatic persons, the presence of CAC was highly sensitive
(98%) in predicting a luminal stenosis >50% in any coronary
artery. In fact, recent ACC/AHA guidelines also consider
that “for the symptomatic patient, exclusion of measurable
coronary calcium may be an effective �lter before under-
taking invasive diagnostic procedures or hospital admission”
[15, 19].
Furthermore, data in patients undergoing myocardial
perfusion scanning (MPS) also have low riskwhenCACscans
show no calci�cations. One prognostic study simultaneously
evaluating the prognostic value of bothMPS and CAC scores
conclusively showed that the event risk of a person without
CAC was extremely low regardless of whether they had
ischemia or not [21]. In fact, none of the patients without
CAC who had an abnormal MPS suffered an event, while a
very low percentage of those without CAC and a normalMPS
suffered an adverse outcome (0% versus 0.2%, resp.). e
2010 ACCF appropriateness criteria state that a low calcium
score (especially in the absence of CAC) precludes the need
for MPS assessment [22], and this is reiterated in the 2010
ACCF guidelines [2].
For event-driven analysis, Blaha et al. [11] showed that
there were 104 deaths (0.52% event rate) among patients with
CAC score zero (19,898 patients) compared with patients
with CAC score >10 (3.96% event rate). e annualized all-
cause mortality rates for CAC score zero and CAC >10 were
0.87 and 7.48 deaths/1,000 person-years. CAC score of zero
separates the very low-risk group from subjects that are at
relatively higher risk for future adverse cardiovascular events
whether the amount of CAC isminimal or signi�cant. Budoff
et al. [23] performed an analysis in a multiethnic population
of MESA study where they showed that the CAC score of
zero (3,415 individuals) was associated with 17 CHD events
(0.1%/year) compared with 11 in those with CAC of 1 to
10 (2% event rate). In age- and gender-adjusted analysis,
presence of minimal CAC (1 to 10) was associated with
an estimated 3-fold higher risk of a hard CHD event (HR:
3.23; 95% CI: 1.17–8.95) which remained robust even aer
adjustment for traditional cardiovascular risk factors and
carotid intimamedia thickness. Raggi et al. [24] followed 632
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patients for a mean of 32 ± 7 months for the development
of acute myocardial infarction or cardiac death. A zero score
was associated with a 0.11% per year event rate, compared
to 4.8% per year with a score >400. ey demonstrated
the incremental bene�t of adding calcium scores to con-
ventional risk factors. Multiple logistic regression analyses
demonstrated that the CAC score percentile was the only
signi�cant predictor of events and provided incremental
prognostic value when added to traditional risk factors for
CAD (chi-square, 𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃𝑃). is study both demonstrated
the prognostic importance of a high score and the potential
to rule out CAD with a CAC of zero. Greenland et al. [2],
in a summary of multiple studies, showed that asymptomatic
patients with CAC score zero had a low event rate (0.1%/year)
over the 3 to 5 years period in ACC/AHA clinical consensus
document. Similarly, in MESA study, subjects with CAC
score 0 had an exceptionally low CVD event rate in an
ethnically diverse subject population [4]. Due to extremely
low event rate in subjects with CAC score of zero, it is being
used to exclude CAD as the cause of chest pain in low risk
patients in NICE clinical guidelines in Britain [25].
5. CAC in Lower-Risk Populations
Traditional risk factor assessment has been shown to under-
estimate coronary risk in certain population groups especially
women and young adults [26–28]. is may lead to subop-
timal medical management for their coronary risk factors.
CAC may help to re�ne the risk strati�cation and treatment
strategies of these patient populations who are otherwise
categorized as low risk based on FRS categorization. Among
3,601 women in MESA study [12], 90% of women were in
the low-risk category according to FRS categorization aer
excluding women with diabetes and older than 79 years of
age. In this group, >30% of women were found to have
CAC score >0, whereas the prevalence of signi�cant CAC
(≥300) was four percent. e hazard ratio of coronary heart
disease in women with CAC score >0 was 6.5 (95% CI;
2.6–16.4) compared with women with CAC score of zero.
Berry et al. studied incidence and progression of subclinical
atherosclerosis in young adults ≤50 years of age in subjects
enrolled in Coronary Artery Risk Development in Young
Adults (CARDIA) and MESA study [29]. ey found that
individuals with low 10-year but high lifetime risk have a
greater subclinical atherosclerotic burden on carotid IMT
andCACand greater incidence of atherosclerotic progression
compared to individuals with low 10-year and low lifetime
risk. In light of these and other data, current practice
guidelines suggest that physicians consider current risk factor
burden within the context of long-term or lifetime risk for
CVD [30–32].
�. Risk �ene�t o� Coronar� Arter� Cal�i��ation
CAC is a noninvasive measure of atherosclerosis; however, its
use is associated with certain radiation exposure andmedical
cost. Budoff et al. [33] evaluated cost of CAC testing com-
pared toMPS algorithms for evaluation of CAD aer border-
line or abnormal exercise treadmill test. Evaluating patients
with abnormal treadmills led to direct cost savings of $873
per patient for the baseline case. ey concluded that CAC
followed by selective CTA-based strategies lowered overall
health care costs, primarily by decreasing the rate of false-
positive examinations, thereby leading to fewer angiograms.
Rozanski et al. [34] performed a prospective, randomized
trial evaluating the direct impact of CAC on future CAD
risk and downstream medical cost compared to that of
the conventional medical practice, in the EISNER (Early
Identi�cation of Subclinical Atherosclerosis by Noninvasive
Imaging Research) study. ey evaluated 2,137 volunteers
to undergo CAC scanning or randomized not to undergo
CAC scanning before risk factor counseling. e primary
end point of the trial was 4-year change in CAD risk factors
and FRS. Compared with no scan group, the scan group
showed a net favorable change in systolic blood pressure (𝑃𝑃 𝑃
𝑃𝑃𝑃2), low-density lipoprotein cholesterol (𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃), and
waist circumference for those with increased abdominal girth
(𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃) and tendency to weight loss among overweight
subjects (𝑃𝑃 𝑃 𝑃𝑃𝑃7). FRS remained static in the scan group
compared with no scan group (𝑃𝑃𝑃𝑃2 ± 𝑃𝑃9 versus 𝑃𝑃7 ± 5𝑃𝑃,
𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃3). Within the scan group, increasing baseline
CAC scorewas associatedwith a dose-response improvement
in systolic and diastolic blood pressure (𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃𝑃), total
cholesterol (𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃𝑃), low-density lipoprotein cholesterol
(𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃𝑃), triglycerides (𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃𝑃), weight (𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃𝑃),
and FRS (𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃3). e EISNER study also prospectively
evaluated the procedural cost and resource consumption
patterns aer CAC measurement during the 4-year followup
period using Medicare reimbursement rates. ey showed
that downstream frequency of medical tests and costs was
signi�cantly lower in those persons who had CAC zero as
compared to those who did not receive a CAC scan.
LaMonte et al. [35] studied 10,746 adults aged 22 to 96
years and free of known CAD. e individuals were studied
by electron beam tomography (EBT) for coronary calcium
assessment as part of a preventive medical examination.
During a mean follow-up of 3.5 years, 81 hard events (CAD
death, nonfatal MI) and 287 total events (hard events plus
revascularization) occurred. e age-adjusted rates of hard
coronary events per 1,000 person-years in four categories
of calcium scores (0, 1–99, 100–399, 400, or above) were
0.4, 1.5, 4.8, and 8.7 for men and 0.7, 2.3, 3.1, and 6.3
for women (signi�cant in men and women). Even aer
risk factor adjustment, the association between calcium and
events remained signi�cant, and signi�cant cost savings were
appreciated.
7. CAC Progression
While baseline scores have proven clinically and prognosti-
cally important, cost effective, and better than other markers
of CV risk in all studies published, data on progression
of CAC is more divergent. e most comprehensive study
of factors associated with progression of CAC was the
MESA study [36]. In the MESA cohort, many traditional
cardiovascular risk factors were associated with both the risk
of developing incident coronary calcium and increases in
existing calci�cation. ese included older age, male gender,
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white race/ethnicity, hypertension, higher body mass index,
diabetes mellitus, and family history of heart attack. Diabetes
mellitus was the strongest risk factor for CAC progression. In
fact, glucose was associated with higher risk of incident CAC
even at levels well below the standard thresholds for diabetes
mellitus or impaired fasting glucose and among nondiabetic
participants. Among treated diabetics, duration of diabetes
was the only signi�cant risk factor for CAC progression
aer adjustment for age, gender, scanner, and duration of
follow-up. Certain factors also appeared to be related only
to the risk of incident CAC but not to the progression
of existing calci�cation. For instance, LDL cholesterol and
HDL cholesterol were not associated with the progression
of existing CAC, but both were associated (HDL negatively)
with the risk of incident CAC. Triglycerides were associated
with both end points in models adjusted for age, gender, and
follow-up time, but in fully adjusted models, this association
became nonsigni�cant for CAC progression while remaining
signi�cant for incident CAC. Although both �brinogen and
CRP were related to an increased risk of incident CAC,
this became nonsigni�cant aer adjustment for body mass
index.
7.1. Predictive Value of Serial CAC Score Progression. e
real question becomes as follows: “are CAC progressors
at increased risk for CVD, or is CAC progression just a
representation of increased scar tissue?” Atherosclerosis is a
dynamic process which may be affected by traditional risk
factors, environmental factors, and therapeutic interventions
[36–39]. Baseline CAC represents a single point in time on
atherosclerosis time curve, whereas progression presents the
slope of that curve. CAC progression may provide insight
into ongoing atherosclerotic disease activity. erefore, CAC
progression might represent a better marker of disease
activity a better predictor of future adverse cardiovascular
events and can be used to evaluate the effect of various
therapeutic interventions. Measurement of CAC progression
highly depends on accurate reproducibility of CAC scores,
which will be discussed in detail in a later section [37, 38].
Budoff et al. showed that CAC progression was signif-
icantly associated with mortality even aer adjusting for
baseline CAC, age, sex, time between scans, hypertension,
hypercholesterolemia, diabetes, family history, and smoking
(hazard ratio = 3.32, 95% CI: 2.62–4.20, 𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃𝑃𝑃) in
4,609 consecutive asymptomatic individuals undergoing two
scans. Adjusted models showed that the presence of CAC at
baseline and associated signi�cant progression of CAC was
a signi�cant predictor of future mortality (HR: 5.33, 95%
CI: 3.74–7.60, 𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃𝑃𝑃) [40]. is study also evaluated
various methods of CAC progression estimation and their
performance in predicting future mortality (absolute score
difference, percent annualized difference between baseline
and followup scans, and the difference between square root
of baseline and square root of followup CAC score >2.5
(the SQRT method)). e SQRT method was found superior
followed by percent increase in CAC score (>15% yearly
increase) in predicting mortality [41]. Raggi et al. [42] in an
observational study related the occurrence of acute myocar-
dial infarction to CAC progression in 817 asymptomatic
individuals referred for sequential CAC scanning (average
interval 2𝑃2 ± 𝑃𝑃3 years). Mean absolute and percent changes
in CAC score were 147% and 47%, respectively, in those who
developed amyocardial infarction (MI) aer the second scan,
compared to 63% and 26% in those without events (𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃𝑃
and 𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃, resp.). In this study, CAC progression was
the strongest predictor of myocardial infarction. In another
study with 495 asymptomatic subjects undergoing sequential
CAC scans and statin therapy aer the initial scan, Raggi et
al. showed that subjects having myocardial infarction had a
greater annual change of CAC scores compared with those
who did not had an event (42% ± 23% versus 𝑃7% ±
25%, 𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃𝑃𝑃), respectively [43]. Relative risk of having
myocardial infarction in the presence of CAC progression
was 17.2-fold (95% CI: 4.1 to 71.2) higher than without
CAC progression (𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃𝑃𝑃𝑃. e follow-up CAC score
(𝑃𝑃 𝑃 𝑃𝑃𝑃34𝑃 and a score change >15% per year (𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃𝑃𝑃
were shown to be independent predictors of time to MI.
e St. Francis Heart Study [3] prospectively evaluated the
prognostic accuracy of CAC progression in the prediction
of cardiac events in 4,613 adults between 50 and 70 years
of age. Follow-up was over 4.3 years, and events occurred
in 119 subjects (2.6%). Median increase in CAC score was
signi�cantly higher in those with cardiac events compared
with those without events (247 versus 4), respectively. In
multiple logistic regression, two-year change in calcium score
(𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃𝑃𝑃𝑃 was the strongest association with subsequent
CAD events. Several smaller studies have also been reported.
Raggi et al. followed 269 asymptomatic subjects for 2.5 years
aer being submitted to sequential CT scans; of the 22 CVD
events, 20 occurred in patients with progression of CAC
and 2 without progression (𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃𝑃 [44]. Another study
of 225 subjects followed for an average of 3 years aer the
repeat CT scan, and those with new cardiac events had a
signi�cantly greater annual change in CAC score than those
who did not experience events (35% versus 22%, 𝑃𝑃 𝑃 𝑃𝑃𝑃4)
[45]. Moreover, 78% of patients with events had >20% annual
progression versus 37% of those not experiencing events (𝑃𝑃 𝑃
𝑃𝑃𝑃𝑃𝑃𝑃.
e largest andmost comprehensive study of progression
has just been reported.eMulti-Ethnic Study of Atheroscle-
rosis (MESA) has just reported the outcomes associated
with progression of CAC [46]. MESA studied 6,778 persons
(52.8% female) aged 45–84 years from theMulti-Ethnic Study
of Atherosclerosis. 5,682 persons had baseline and follow-
up CAC scans approximately 2𝑃5 ± 𝑃𝑃8 years apart; multiple
imputation was used to account for the remainder (𝑛𝑛 𝑃
𝑃, 𝑃96𝑃 missing follow-up scans. Median follow-up duration
from the baseline was 7.6 (max = 9.0) years. CAC change was
assessed by absolute change between baseline and follow-up
CAC. Cox proportional hazards regression providing hazard
ratios (HRs) examined the relation of change in CAC with
CHD events, adjusting for age, gender, ethnicity, baseline
calcium score, and other risk factors. 343 total and 206 hard
CHD events occurred. e annual change in CAC averaged
24𝑃9 ± 65𝑃3 units. Among persons without CAC at baseline,
(𝑛𝑛 𝑃 3, 396𝑃, a 5-unit annual change in CAC was associated
with an adjustedHRof 1.4 (1.0–1.9) for total and 1.5 (1.1–2.1)
for hard CHD. Among those with CAC >0 at baseline,
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HRs (per 100-unit annual change) were 1.2 (1.1–1.4) and
1.3 (1.1–1.5), respectively. Among participants with baseline
CAC, those with annual progression of ≥300 units had
adjusted HR’s of 3.8 (1.5–9.6) for total and 6.3 (1.9–21.5)
for hard CHD compared to those without progression. ey
concluded that progression of CAC is associated with an
increased risk for future hard and total CHD events.
ese studies suggested that continued accumulation
of CAC in asymptomatic individuals is associated with
increased risk of future MI. e strength of serial CAC
assessment is to evaluate the ongoing activity of atheroscle-
rosis, while CAC offers a measure of lifetime accumula-
tion of atherosclerosis. However, measure of progression is
dependent upon a positive (nonzero) calcium score. Baseline
zero scores were not predictive of progression or all-cause
mortality in the MESA study [46]. is further validates the
concept that a baseline zero score has a signi�cant warranty
period for both future cardiovascular events and progression
of atherosclerosis. Studies have suggested that a zero calcium
score affords at least a 5-year warranty period [45–48]. In the
study by Min et al. [48], the cumulative rate of “conversion”
from a zero CAC score to ≥1 CAC score was 15% in the
�rst 4 years and 25% in the ��h year concluding that 4 years
might be the ideal “warranty period” for a zero CAC score
which is considerably longer than the warranty period that is
offered by normal functional imaging tests (such as nuclear
perfusion scans) which is considered to be around 1.5 to
2 years [49]. A 5-year follow-up study by Gopal et al. [47]
showed that only 2% of patients with baseline zero calcium
score hadCACprogression>50 suggesting that in individuals
with no detectable CAC on an initial scan, a repeat scan can
be recommended no sooner than 5 years.
7.2. Pathogenesis of Progression. e presence of calcium in
coronary arteries is pathognomonic of atherosclerosis, but
the pathogenesis of increasing CAC is still under some debate
[50, 51]. e close correlation between the atherosclerotic
plaque burden and the extent of CAC has been con�rmed
by both histopathology and intravascular ultrasound [52–
55]. �hile CAC detected and quanti�ed by CT represents
an accurate anatomic measure of plaque burden, it only rep-
resents approximately 20% of total coronary plaque burden
[56, 57]. Assessment of CAC progression has been regarded
as a dynamic measurement that might provide insight into
ongoing current disease activity and more efficiently predicts
future cardiac events, by its association with increased total
plaque burden, rather than static traditional clinical param-
eters and baseline CACS [58, 59]. CAC has been widely
suggested as a tool to monitor the progression of coronary
plaque burden and to document the success of risk factor
modi�cation and medical intervention [60, 61].
7.3. Calcium Score Reproducibility. Typically, coronary cal-
cium, untreated, progresses at 10% of the baseline value
per year, although data suggest that a progression rate of
>15% per year is associated with a 17-fold increased risk for
incident CAD events [42]. e accuracy and reproducibility
of the test are paramount to use serially to monitor effects
of therapy [37, 38]. ere have been multiple studies of
reproducibility done using CAC, starting with the earliest
iterations of electron beam tomography and progressing
to 64+ multi-detector computed tomography. Early studies
have demonstrated mean reproducibilities of 14–38% using
scanner or scanning algorithms that are no longer up to date
[61–67]. Improvements in hardware, coupled with improved
algorithms for acquisition and analysis of the calcium data,
have resulted inmarked improvements in reproducibility [68,
69]. A study of 1,376 asymptomatic individuals undergoing
sequential scanning resulted in an average variability of
15–17% [70]. A recent study using a newer scanning protocol
revealed a mean interscan variability of 16–19.9% and a
median variability of 4–8% [71]. Another improvement was
the introduction of the volume score, relying on isotropic
interpolation to better quantitate the CAC burden and
further reduce variability [72–74].
However, with the more recent MDCT scanners, better
image quality signi�cantly contributed to improve repro-
ducibility [75]. Currently, median interscan variability is
about 7%, and mean interscan variability is 15%withMDCT,
allowing serial followup at no closer than 1-year intervals.
7.�. CAC �uanti�cation. CAC scanning can be used to
noninvasively track changes of coronary atherosclerosis by
periodically quantifying CAC [76] and thereby demonstrat-
ing the effects of therapy on this process. Several studies have
been conducted to evaluate the progression of CAC over time
using one of two methodologies for scoring.
CAC�, as measured on cardiac CT, is de�ned as a
hyperattenuating lesion above a threshold of 130 Houns�eld
units (HUs) with an area ≥3 adjacent pixels (at least 1mm2).
ere are currently 2 CT calcium scoring systems widely
used: the original Agatston method [76] and the volumetric
score method [37]. e Agatston score method involves
multiplication of the calcium area by a number related to
CT density. Densities between 130 and 199 receive a score
of 1, between 200 and 299 a density factor of 2, between
300 and 399 is a 3, and ≥400 a multiplicative factor of 4. A
calcium score is reported for a given coronary artery and for
the entire coronary system; however, most research studies
have reported data related to the summed or total score for
the entire epicardial coronary system. Janowitz et al. [66]
demonstrated that the score progression was more marked in
patients with obstructive CAD compared with patients who
had no clinicalmanifest disease (27% versus 18%). One study,
although relatively small (𝑛𝑛 𝑛 𝑛𝑛𝑛, demonstrated an increase
in the CAC score by 24% each year since baseline [61]. A
larger study (𝑛𝑛 𝑛 2𝑛𝑛𝑛 with an average of 2.2-year followup
demonstrated that CAC scores increased by a mean of 33%
per year, predicting that the CAC score will more than double
every 2.5 years on average [60]. Mitchell et al [77] followed
347 patients for 1.4 years, demonstrating an annual average
increase in CAC scores of 21% in men and 18% in women.
A small study of young patients with end-stage renal disease
demonstrated amean calcium score rise of 59% per year, with
a doubling of score by 20 months [78].
Effect of Treatment on CAC Progression.e controversies
related to CAC progression are that there are inconsistent
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relationships between medications known to be bene�cial
and rates of CAC progression. Statins reduce clinical cardiac
end points across a spectrum of patient populations [79–82].
It seemed intuitive to early researchers that statin therapy
should reduce the progression of CAC. Callister et al. pro-
duced the �rst report of CACS being used to assess the effects
of statin therapy [83]. ey conducted a retrospective study
of 149 patients with no history of CAD. Repeat scanning was
carried out 12–15 months later. 105 patients received statin,
and a net reduction in CAC score was found in the treated
group who had �nal LDL-cholesterol levels <3.10mmol/L
(−7 ± 23%; 𝑃𝑃 < 𝑃𝑃𝑃𝑃𝑃). Treated patients who had an average
LDL-cholesterol of ≥3.10mmol/L had an increase in CAC
score (+25 ± 22%; 𝑃𝑃 < 𝑃𝑃𝑃𝑃𝑃); further increases were noticed
in untreated patients who had an average LDL-cholesterol of
≥3.10mmol/L (+52 ± 36%; 𝑃𝑃 < 𝑃𝑃𝑃𝑃𝑃𝑃).
In another prospective study, 66 patients whowere not on
treatment and whose LDL-cholesterol was >3.4mmol/L, had
a repeat EBCT, and treatment with Cerivastatin 0.3mg/day
was initiated aer a mean interval of 14 months [84]. A third
examination was carried out aer 12 months of treatment;
the median annual relative increase in CAC score was 25%
during the untreated period versus 8.8% in the treatment
period (𝑃𝑃 < 𝑃𝑃𝑃𝑃𝑃𝑃𝑃.
In the observational study by Budoff et al. [60], 123
persons with hypercholesterolemia were followed. e par-
ticipants reporting use of a statin (𝑛𝑛 𝑛 6𝑃𝑃 had an annual
rate of progression of 15%, compared with 39% annual
increase in EBT score for the 62 persons in the nontreat-
ment group (𝑃𝑃 < 𝑃𝑃𝑃𝑃𝑃𝑃. is represented a 61% reduction
in the rate of progression obtained with statin therapy.
A study of 160 persons with established coronary artery
disease has demonstrated that treatment of patients with
severe hypercholesterolemia has resulted in a slowing of the
atherosclerotic CAC process [85]. Combination treatment
with simvastatin, niacin, and Vitamin E resulted in an annual
calcium score progression of 20% as compared to a median
of 40% progression measured in the untreated group.
Rath and Niedzwiecki [86] demonstrated the effect
of nutritional supplements (a combination of vitamins,
minerals, and coenzymes) on progression of CAC in 55
persons. Patients treated with the nutritional supplements
demonstrated an annual progression of 15%, while untreated
patients progressed at a rate of 44%.
However, prospective randomized trials did not support
the earlier observational results that statins could slow CAC
progression. St. Francis Heart Study is a double-blinded,
placebo-controlled, randomized clinical trial where 1005
asymptomatic men and women aged 50–70 years with CAC
score ≥80th percentile for age and gender were randomized
to receive either Atorvastatin 20mg daily and vitamin E (𝛼𝛼-
Tocopherol) 1000 units daily or placebo [87] with mean
duration of treatment of 4.3 years. Treatment reduced total
cholesterol by 26.5–30.4%, LDL-cholesterol by 39–43%, and
triglycerides by 11.2–17%, but had no effect on progression of
CAC score. More importantly, the treatment with statins did
reduce CV events by 42% (𝑃𝑃 < 𝑃𝑃𝑃5𝑃 in those persons taking
statins as compared to the placebo group, demonstrating
de�nitively that persons with CAC bene�t by treatment with
statins.
In another multicenter, randomized double-blind trial
[88], 471 patients had ≥2 cardiovascular risk factors and a
CAC score of ≥30 with no history of CAD or evidence of
signi�cant coronary stenoses. Patients were randomized to
receive either low- (10mg) or high-dose (80mg)Atorvastatin
over 1 year. LDL-cholesterol was reduced in the 80mg/day
group from 2.7 to 2.2mmol/L, whereas in the 10mg/day
group, it remained at 2.8mmol/L. e mean progression
in 366 patients corrected for baseline score was 27% in
the 80mg/day group compared with 25% in the 10mg/day.
us, no difference was found in the progression between
the two groups, and no relationship was found between
on-treatment LDL-cholesterol and progression. Accordingly,
several factors might explain this con�icting data� (1) �rst
statins may cause microcalci�cations, which could increase
the CAC score while decreasing the lipid core, (2) longer
followup period are needed, or (3) statinsmight be improving
the cardiovascular outcome through other pleiotropic effects
rather than mere lowering of the LDL-cholesterol or decreas-
ing the CAC scores.
Several prospective randomized trials of garlic ther-
apy on CAC have shown consistent improvement in CAC
progression [89–92], suggesting that the microcalci�cations
may be the cause of inconsistent data related to statins
and progression of CAC. CAC progression adds signi�cant
incremental prediction ability of all-cause mortality, aer
adjustment for time between scans, demographics, risk fac-
tors, and baseline CAC scores. It appears that persons with
scores >30 can be assessed for progression of CAC, and this
adds incremental information regarding future prognostic
risk. ough utilization of repeat CT testing to estimate an
individual’s risk associated with CAC “change” appears to be
of value, a better understanding of what therapies may be of
bene�t and how clinicians should utilize these data in clinical
practice remains to be determined.
8. Radiation
e radiation exposure associated with CAC scans has been
signi�cantly reduced, now comparable to 1-2 mammograms
(∼1mSv) [15, 93–97] while providing important information
about the subject coronary risk and cardiac anatomy. Mea-
suring CAC progression requires sequential CT scans, with
a cumulative radiation exposure. Prior reports have raised
concern about the excess risk of cancerwith such an approach
[98]. However, such predictions are outdated as current
gating technology reduces the radiation dose substantially,
with an expected dose of <1 millisievert (mSv) per scan [99].
Further advances have reduced the CAC dose to as low as
0.6mSv, lower than screening mammography [99, 100].
9. Conclusions
e cumulative data provides strong con�rmatory evidence
that CAC is a strong predictor of events and that CAC
progression is associated with future cardiovascular events
and that, as radiation doses are being reduced to a minimum,
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may be a useful tool in the prevention armamentarium to
assess atherosclerosis progression noninvasively. Based on
available published evidence, CAC has been incorporated
into the ACC/AHA guidelines for screening of asymptomatic
individuals for CVD. CAC has been advocated as a screening
tool for risk assessment of asymptomatic adults at interme-
diate risk (10%–20% 10-year risk), low-to-intermediate risk
(6%–10% 10-year risk), and patients with diabetes [2].
A scienti�c statement from the AHA [15] agree that with
the statement from the AHA perspective paper [57], which
stated that “…with a prior probability of a coronary event
in the intermediate range (≥6% in 10 years but ≤20% in
10 years), a calcium score of >100 would yield a post-test
probability in virtually all such patients greater than 2% per
year, that is, a level similar to that in secondary prevention, or
a ‘coronary risk equivalent.”’ erefore, all patients with CAC
>100 should be considered for statin therapy, aspirin, and
possibly ACE inhibition, given the increased cardiovascular
risk associated with this level of coronary atherosclerosis,
concurring with the current NCEP Adult Treatment Panel
(ATP) III guidelines [30]. is supports the conclusions of
the Prevention Conference V and the AHA report [15] that
high coronary calcium scores con�rm increased risk for
future cardiac events: “measurement of coronary calcium
is an option for advanced risk assessment in appropriately
selected persons. In persons with multiple risk factors, high
coronary calcium scores (e.g., >75th percentile for age and
sex) denote advanced coronary atherosclerosis and provide a
rationale for intensi�ed LDLC lowering therapy. Moreover,
measurement of coronary calcium is promising for older
persons in whom the traditional risk factors lose some of
their predictive power.” e severity of CAC can identify
asymptomatic patients at high risk for CAD. e resulting
calcium score in the respective category can be used to stratify
an asymptomatic person’s risk for a future cardiac event.
Accordingly, either modi�cation of risk factors or further
testing can be pursued to reduce the likelihood of such an
event from happening [58]. For persons at high risk, an
accurate and noninvasive measure of atherosclerosis could
allow better assessment of processes associated with disease
progression and of therapies to prevent the progression of
atherosclerosis and clinical CAD [59].
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